CSIMarket
 


Sage Therapeutics Inc   (SAGE)
Other Ticker:  
 

Cumulative Sage Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

SAGE's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

SAGE Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 26.43 % 8.48 % 8.99 % 16.51 % 26.28 %
Y / Y Current Assets Growth -36.3 % -32.61 % -28.46 % -25.75 % -22.96 %
Working Capital Ratio for Trailing Twelve Months Period 11.15 13.33 14.98 16.57 18.55
Total Ranking # 243 # 207 # 189 # 184 # 173
Seq. Current Liabilities Growth 30.19 % 14.3 % -14.68 % -0.43 % 11.71 %
Seq. Current Assets Growth -12.29 % -11.58 % -9.99 % -8.75 % -7.21 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to growth in Current Liabilities in the III. Quarter to $126 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 11.15 below Sage Therapeutics Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 163 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Sage Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about SAGE
Working Capital Ratio SAGE in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 164
Sector # 273
S&P 500 # 419


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
28.8 16.16 6.02
(Sep 30 2021)   (March 31, 2014)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Aprea Therapeutics Inc   29.68 
Gh Research Plc  29.57 
Dice Therapeutics Inc   29.08 
Atossa Therapeutics Inc   28.99 
Design Therapeutics Inc   28.09 
Eliem Therapeutics Inc   27.09 
Mineralys Therapeutics Inc   27.08 
Briacell Therapeutics Corp   26.16 
Imago Biosciences Inc   25.95 
Xenon Pharmaceuticals Inc   25.51 
Theseus Pharmaceuticals Inc   25.00 
Terns Pharmaceuticals Inc   24.47 
Rezolute Inc   24.17 
Cyteir Therapeutics Inc   24.12 
Eqrx Inc   24.02 
Astria Therapeutics inc   23.94 
Belite Bio Inc  23.14 
Artelo Biosciences Inc   22.20 
Disc Medicine Inc   22.15 
Diamedica Therapeutics Inc   21.10 
Savara Inc   21.02 
Minerva Neurosciences Inc   21.00 
Prometheus Biosciences Inc   20.91 
Kezar Life Sciences Inc   20.76 
Akero Therapeutics Inc   20.69 
Janux Therapeutics Inc   20.57 
Edgewise Therapeutics inc   20.54 
Pmv Pharmaceuticals Inc   20.33 
Nextcure Inc   20.32 
Kura Oncology Inc   19.97 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com